Sun Pharma launches first branded ophthalmic product BromSite in US
Developed by its California-based subsidiary, InSite Vision, the product is also the first bromfenac ophthalmic solution formulated in DuraSite, a polymer-based drug delivery system Sun Pharma launches first branded ophthalmic product, BromSite, in USA
Sun Pharmaceutical Industries Ltd has informed BSE regarding a Press Release dated November 28, 2016 titled "Sun Pharma launches first branded ophthalmic product, BromSite, in USA". Regulatory issues keep Sun Pharma stock under cloud
Stock is 40% below its all-time high touched last year
ICMR-Sun Pharma group to moot drug regulatory, vaccine development overhaul
The group is likely to prioritize a list of diseases that a larger working group, comprising of representation from the drug regulator and pharmaceutical firms, will focus on before the next meeting Near term growth concerns to weigh on Sun Pharma
Regulatory clearances remain crucial for US growth
Sun Pharma's Mohali unit violated manufacturing norms, finds US FDA
USFDA inspected Sun Pharma's Mohali plant and cited seven deviations from norms Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Pratham Investments
Sun Pharma to acquire 85% in Russian firm Biosintez for $24 million
Sun Pharma will assume $36 million debt of Biosintez, which focuses on the hospital segment and posted $52 million revenue last year Sun Pharma to acquire Biosintez in Russia
Sun Pharmaceutical Industries Ltd has informed BSE that the Company (including its subsidiaries and/or associate companies), has entered into an agreement to acquire 85.1% of JSC Biosintez, a Russian pharmaceutical company engaged in manufacture and marketing of pharmaceutical products in Russia and CIS region. Updates
Sun Pharmaceutical Industries Ltd has informed BSE that the Company have received a letter intimating to the Company from the Company's Chief Financial Officer (CFO), Mr. Uday Baldota that he would be tendering his resignation as the CFO of Sun Pharmaceutical Industries Limited to be effective with effect from in and around April, 2017 due to his shifting to United States of America in and around April, 2017 to look after the business of Taro Pharmaceutical...